Navigation Links
EMA Starts Formal Review of Glybera(R) Dossier
Date:1/25/2010

pectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. AMT Starts Preregistration Trial for Glybera(TM)
3. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
4. BioCis Pharma Starts Phase IIa Trial in Psoriasis
5. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
6. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
11. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... Inc. (NYSE: MDT ) has submitted ... and Drug Administration (FDA) for the use of ... system (including a newly developed catheter) for use ... delivered intravenously to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... December 23, 2014 “Preparative & ... HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, ... & Agriculture) - Forecasts to 2019” provides a ... opportunities, current market trends, and strategies impacting the ... estimates and forecasts of the revenue and share ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... and Continuing Resolution Appropriations Act of 2015, which ... eligible to receive funding through the Congressionally Directed ... of Defense (DoD). The Hydrocephalus Association (HA), working ... is celebrating this victory for the over 1 ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... NATURAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) today announced ... the Company to "Fully Compliant", its highest tier for ... over-the-counter into easily identifiable tiers that inform investors whether ... a timely manner. Subsequent to NFI,s recent filing, ...
... Hands-On Exhibition Brings Big Focus to Microscopic World , ... Baltimore, MD ... exhibition, Cells: The Universe Inside Us, the Maryland Science Center takes the ... on the human body. The result is a 4,000 square foot exhibit ...
... ProgramST. LOUIS, March 26 SAFC Biosciences(TM), a leading ... and downstream processes in the biopharmaceutical industry and a ... Group (Nasdaq: SIAL ), today announced it ... culture media continuous milling production site in Lenexa, Kansas ...
Cached Biology Technology:Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2Cells Exhibition Opens at Maryland Science Center 2Cells Exhibition Opens at Maryland Science Center 3SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 3SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 4
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a leader ... million in Series A1 funding led by UK-based Eurovestech. ... participated in the investment round. "We are ... community adopts next-generation sequencing and seeks new approaches for ... Reid Robison , MD MBA, and CEO of Tute ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... II, US nautical charts have shown seven "chemical munitions ... and the Mexican border. However, little or no information ... the materials that were dumped at most of these ... Union in San Francisco, researchers from the Monterey Bay ...
... The purpose is to submit the data obtained to the ... line with medical advances in this field. On 4 December ... the Political Sciences Research Centre in Paris (CEVIPOF) for the ... of regenerative medicine , Today, human biological specimens are seen ...
... cute. They have a thick fur, fly somewhat clumsily ... are very much appreciated by farmers as keen pollen ... populations, the buff-tailed bumblebee, Bombus terrestris , is ... of fruit and vegetable crops both inside and outside ...
Cached Biology News:Survey of supposed deep-sea chemical munitions dump off Southern California 2Survey of supposed deep-sea chemical munitions dump off Southern California 3EUCelLEX Project: Assessment of the social issues raised by the use of regenerative medicine in Euro 2EUCelLEX Project: Assessment of the social issues raised by the use of regenerative medicine in Euro 3Peaceful bumblebee becomes invasive 2Peaceful bumblebee becomes invasive 3
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
... Rat adult normal paraffin tissue array ... or proteins of interest in extensive ... Rat brain, heart, kidney, liver, ... are arrayed on positively charged glass ...
... ml. Improves reproducibility and quality ... streaking.Eliminates extra spots caused by ... throughout entire 2-D runs, ensuring ... for both analytical and preparative ...
GENOMIPHI HY KIT 1000 RXN, 1 EA. Category: Genomics DNA Amplification....
Biology Products: